gms | German Medical Science

Purpose: Since July 2010 in Germany the therapy of macular oedema by retinal vein occlusion with Ozurdex^® (Allergan) is approved. In this lecture the 2, 6 and 12 months results of the St.-Johannes-Hospital in Dortmund should be presented.

Methods: In this retrospective analysis we present the results of 102 eyes. 48 eyes with central vein occlusion and 54 eyes with branch vein occlusion. These eyes were treated with Ozurdex (Dexamethason) and the maximum follow up was after 12 months. The main assessment were the central retina thickness in the OCT, the best visual acuity and the implantation frequency. Furthermore we distinguished between eyes with and without intravitreal pretherapy.

Results: On average in both groups were a significant improvement of the vision: after 2 months (12 months) by 5.24 (6.92) letters in the branch vein group and by 7.00 (6.38) in the central vein group. The central retina thickness was reduced to 277.24 µm (325.29) in the branch vein group and to 201.64 µm (154.5) in the central vein group. In the 12 months we re-injected Ozurdex in 2.25 times.

Conclusions: Therapy with Ozurdex shows in clinical routine also after 12 months and re-injection several times a very good improvement of the vision and reducing of macula oedema. The maximum improvement of the vision is 2 months after the application of Ozurdex. In the branch vein group the results after 12 months shows continuously trend to functional recovery.